Benralizumab is noninferior to mepolizumab in achieving remission of relapsing or refractory eosinophilic granulomatosis with polyangiitis at 36 and 48 weeks, according to data published in The ...

However, the results suggest that "long-term benralizumab-driven 318 eosinophil depletion results in disrupted airway luminal occlusions and improved airway structure and function," which may ...

BOSTON — Patients taking benralizumab experienced more asthma exacerbations than patients taking mepolizumab, according to an abstract presented at the CHEST Annual Meeting. This study compared ...

Researchers have shown that the drug benralizumab is as effective and safe as mepolizumab for inducing remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) according to ...

Mepolizumab and benralizumab are highly effective for patients with severe eosinophilic asthma, according to a study presented at the American Thoracic Society (ATS) International Conference 2022 ...

Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. The Lancet Respiratory Medicine , 2014; DOI: 10.1016 ...

The real-world Zephyr 2 study, which assessed benralizumab for effectiveness in treating severe eosinophilic asthma, was extended with an analysis of a larger population stratified into three ...

A year's course of benralizumab injections has led to a significant decrease in the frequency of asthma exacerbations -- cutting the rate of exacerbations by a third to a half compared with ...

These compared benralizumab with placebo in people with uncontrolled asthma, taking high-dose inhaled corticosteroids and a long-acting beta-agonist, ... Taking everything into account, the committee ...

The 56-week OSTRO trial evaluated the efficacy and safety of benralizumab, an interleukin-5 antagonist, in 413 adult patients with severe nasal polyposis. Treatment with benralizumab was ...

Researchers in the UK say that AstraZeneca's benralizumab can have a dramatic impact if used to treat acute asthma attacks, calling it the first major advance for this aspect of the disease in 50 ...